Clinical trials: Gastroenteropancreatic Neuroendocrine Neoplasm
Gastroenteropancreatic Neuroendocrine Tumors
Community-based Neuroendocrine Tumor (NET) Research Study
The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot.
- Trial name
- NCT02730104
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ipsen
Neuroendocrine Tumors
Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors
The purpose of this study is to verify if adding a locoregional treatment of liver metastasis (with trans-arterial embolization-TAE) to medical treatments of proven efficacy can prolong the progression free survival of patients…
- Trial name
- LOTUS (NCT01755182)
- Testing
- approved pharmacologic therapy, TAE
- Where
- 12 sites in Italy
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute, Naples
Carcinoma, Neuroendocrine
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
- Trial name
- NCT02250885
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Gabrail Cancer Center Research
Neuroendocrine Carcinoma
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
Neuroendocrine tumors of the lung include the small cell carcinoma (SCLC), and large cell neuroendocrine carcinoma (LCNEC) and represent 20% of lung cancer.
- Trial name
- NIPINEC (NCT03591731)
- Testing
- Nivolumab, Ipilimumab
- Where
- 7 sites in France
- Volunteers
- 185 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Gastroenteropancreatic Neuroendocrine Tumor
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed…
- Trial name
- REAL-LU (NCT04727723)
- Testing
- Lutathera®
- Where
- 18 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes…
- Conditions
- Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1
- Trial name
- NCT03375320
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 432 sites in United States
- Volunteers
- 298 people
- Sponsor
- National Cancer Institute (NCI)
Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).
- Trial name
- NCT02948946
- Testing
- NETest
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Gastroenteropancreatic Neuroendocrine Tumors
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
The purpose of the study is to evaluate the efficacy and tolerability of the combination of Lanreotide Autogel 120 mg and Temozolomide in patients with progressive gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) graded…
- Trial name
- SONNET (NCT02231762)
- Testing
- Lanreotide Autogel 120 mg, Temozolomide (TMZ)
- Where
- 10 sites in Austria, Germany
- Volunteers
- 57 people
- Sponsor
- Ipsen
Patients With Gastroenteropancreatic Neuroendocrine Tumors
TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
Evaluation of the diagnostic performance of PET / CT with 68Ga-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in routine clinical practice (octreoscan ® ; multiphase SPECT / CT…
- Trial name
- 68-DOTANOC-GEP (NCT01747096)
- Testing
- 68-Ga-DOTANOC
- Where
- 5 sites in France
- Volunteers
- 130 people
- Sponsor
- Nantes University Hospital
Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants…
- Conditions
- Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
- Trial name
- NCT07488923
- Testing
- ML261
- Where
- 7 sites in United States
- Volunteers
- 110 people
- Sponsor
- Moonlight Bio, Inc
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3…
- Conditions
- Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT07278479
- Testing
- [212Pb]Pb-MP0712, [203Pb]Pb-MP0712
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Molecular Partners AG
Neuroendocrine Tumors, Neuroendocrine Neoplasm
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
This is a prospective, multi-centre, open label, non-randomized phase II study evaluating the efficacy and safety of nivolumab plus platinum-based chemotherapy in patients with advanced G3 NENs of the GEP tract or of UK origin.
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- NCT03980925
- Testing
- Nivolumab, Carboplatin, Etoposide
- Where
- 12 sites in Spain
- Volunteers
- 37 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery.
- Conditions
- Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor, Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor
- Trial name
- NCT03891784
- Testing
- Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
- Trial name
- LOLA (NCT04427787)
- Testing
- Cabozantinib, Lanreotide
- Where
- Italy
- Volunteers
- 69 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib in patients who have…
- Conditions
- Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
- Trial name
- NCT05773274
- Testing
- Biospecimen Collection, Cabozantinib, Computed Tomography
- Where
- 42 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors
Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment
The aim of this study is to evaluate the financial toxicity reported by Italian patients affected by GEP-NEN during the first year of treatment after diagnosis and its correlations with patient-reported outcomes (PROs) and…
- Trial name
- FiReNEN (NCT05334290)
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Massimo Falconi
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
- Conditions
- Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor
- Trial name
- NCT05636618
- Testing
- [203Pb]VMT-α-NET, [212Pb]VMT-α-NET
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics
Neuroendocrine Tumors, Carcinoma, Small Cell Lung
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocrine tumors or small cell lung…
- Conditions
- Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
- Trial name
- NCT02936323
- Testing
- PEN-221
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 89 people
- Sponsor
- Tarveda Therapeutics
Advanced Solid Tumors
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
This is a multicenter, open-label, single-arm, dose-escalation and dose-expansion Phase I/II study to evaluate the safety, tolerability and preliminary anti-tumor activity of MB0151 in adult subjects (at least 18 years old) with…
- Trial name
- NCT06840821
- Testing
- MB0151 for injection
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Mainline Biosciences (Shanghai) Co., Ltd